Drug Profile
Research programme: lysosomal storage disease enzyme replacement therapies - Angiochem/GlaxoSmithKline
Alternative Names: EPiC-enzymesLatest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator AngioChem; GlaxoSmithKline
- Developer AngioChem; GSK
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Lysosomal storage diseases in Canada (Parenteral)
- 23 Sep 2016 Research development is ongoing for Lysosomal storage diseases in Canada (Parenteral) (Angiochem pipeline; September 2016)
- 27 Feb 2012 Early research in Lysosomal storage diseases in Canada (Parenteral)